Tools for Practice Outils pour la pratique


#329 Coughing up the evidence: Bronchodilators or inhaled steroids for post-infectious cough


CLINICAL QUESTION
QUESTION CLINIQUE
Do bronchodilators or inhaled corticosteroids (ICS) improve post-infectious cough in adults without asthma?


BOTTOM LINE
RÉSULTAT FINAL
Data is very limited with only two ICS randomized controlled trials (RCTs) (163 patients) and one bronchodilator RCT (92 patients). For adults, post-infectious cough scores may improve ~50% on placebo and ~5-10% more with ICS over 2 weeks. Ipratropium/salbutamol may resolve cough in more patients than placebo at day 10 (63% versus 31%) but most patients (>80%, regardless of treatment) will have cough resolution by day 20.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
  • Differences statistically significant unless noted.
  • ICS versus placebo:
    • Four systematic reviews of treatments for persistent cough (4-9 RCTs, 335-750 patients): Interpretation limited by inclusion of RCTs with acute (<3 weeks)1,2 and chronic (>8 weeks)2,3 cough, and multiple drug classes.4  
      • Most useful systematic review2 (2 RCTs, 163 patients), mostly subacute cough (3-8 weeks):
        • ICS 0.42 (standard mean difference) better than placebo. In clinical terms, placebo improved cough scores at ~2 weeks by ~50-56% and ICS improves ~2-13% more.
        • Largest RCT5 (133 patients) also reported:
          • Additional outcomes (days off work, nocturnal awakenings, adverse effects): No difference.
          • Proportion of non-smokers with >50% cough improvement: 81% versus 54% (placebo), number needed to treat (NNT)=4.
            • No improvement among smokers.
          • Limitations: Not all patients had post-infectious cough; study industry funded.
  • Bronchodilators versus placebo:
    • One RCT6 of 92 patients (cough duration 3-4 weeks): Combination of nebulized salbutamol/ipratropium versus placebo.
      • Proportion with ongoing cough at day 10: 37% versus 69% placebo, NNT=3.
      • No difference at day 20 (both >80% resolved).
      • Limitations: Small studies; non-validated cough scores; multiple outcomes.

CONTEXT
CONTEXTE
  • Post-infectious cough is a cough persisting 3-8 weeks after an acute respiratory illness.7
  • One RCT8 compared beclomethasone and placebo in 72 patients with prolonged acute cough (10 days-3 weeks), so likely not true post-infectious (subacute) cough.
    • ICS improved 3 of 6 outcomes over placebo on device-measured cough, but no difference in patient-reported symptoms.
  • Guidelines suggest considering a trial of inhaled ipratropium or, if refractory, inhaled corticosteroids.9
  • RCTs above did not include patients with COVID-19.


Anis Lakha December 12, 2022

A very practical solution for controlling cough 69% is significant if one needs to be able to control cough in public

Janette Hurley December 12, 2022

Excellent

Michael O'Malley December 12, 2022

thanks

Colin Baxter December 12, 2022

Symbicort has definitely helped post Covid cough

Doris Thom December 13, 2022

Interesting!

Peter Wells December 15, 2022

it is common, and getting more so, for patients to ask for something so good to have evidence. I wonder if there are any “harms” as patients despite evidence are grateful for “something”

Albert Lauwers December 29, 2022

Helpful

Ginette Laverdiere January 10, 2023

easy read with useful information

Gulniyaz Abisheva January 10, 2023

Thank you

Ebelechukwu Ejiofor January 19, 2023

I have tried this on several occasions and it has seemed to work for my patients with subacute cough syndromes following a persisting cough


Latest Tools for Practice
Derniers outils pour la pratique

#367 Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines

What are the risks and benefits of ubrogepant for the acute treatment of episodic migraines?
Read Lire 0.25 credits available Crédits disponibles

#366 Looking for Closure: Managing simple excisions or wounds efficiently

What are some options for efficiency in wound closure?
Read Lire 0.25 credits available Crédits disponibles

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Samantha Moe PharmD
  • Emelie Braschi MD CCFP PhD
  • G. Michael Allan MD CCFP

1. El-Gohary M, Hay AD, Coventry P, et al. Family Practice 2013; 30: 492-500.

2. Lee SE, Lee JH, Kim HJ, et al. Allergy Asthma Immunol Res 2019; 11(6): 856-70.

3. Johnstone KJ, Chang AB, Fong KM, et al. Cochrane Database Syst Rev. 2013 Mar 28; (3):CD009305.

4. Speich B, Thomer A, Aghlmandi S, et al. Br J Gen Pract. 2018; 68(675):e694-e702.

5. Ponsioen BP, Hop WCJ, Vermue NA, et al. Eur Respir J 2005; 25 (1): 147-52.

6. Zanasi A, Lecchi M, Del Forno M, et al. Pulm Pharmacol Ther 2014; 29: 224-32.

7. Irwin RS, French CL, Chang AB, et al. Chest 2018; 153(10): 196-209.

8. Gillissen A, Richter A, Oster H. J Physiol Pharmacol 2007; 58 (Suppl 5 Pt 1):223-32.

9. Irwin RS, Baumann MH, Bolser DC, et al. Chest 2006; 129(1 Suppl):1S-23S.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.